GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company today announces its schedule for the publication of FINANCIAL information in 2017 and the date of its 2017 Annual General Meeting.
|30 January 2017||Business & Cash Position Update 4th Quarter 2016|
|28 February 2017||Genticel's shareholders meeting to approve the proposed contribution agreement signed with Genkyotex|
|16 March 2017||2016 Annual Results|
|27 April 2017||Business & Cash Position Update 1st Quarter 2017|
|15 June 2017||Annual General Meeting in Paris, France|
|27 July 2017||Business & Cash Position Update 2nd Quarter 2017|
|21 September 2017||2017 Half-Year Results|
|26 October 2017||Business & Cash Position Update 3rd Quarter 2017|
This financial calendar is for indicative purposes only and Genticel could change its publication dates if deemed necessary.
Each publication will be released after Euronext market closing.
Genticel's versatile platform, Vaxiclase, is well suited for the development of various immunotherapies. A partnership on the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Pvt. Ltd. (Serum Institute), the largest producer of vaccine dose worldwide. This agreement covers territories in emerging markets only, and could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. In November 2016, the last preclinical milestone was reached, opening the path to formal preclinical testing prior to clinical development and subsequent commercialization.
On December 22nd 2016, Genticel signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel's shareholders at a meeting expected to be held in the first quarter of 2017, Genkyotex's shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex's shareholders will hold 80% of Genticel's share capital & voting rights (on a non-diluted basis).
Genkyotex is developing a portfolio of NADPH oxidase (NOX) oral small molecule inhibitors, which have therapeutic potential for the treatment of multiple significant clinical indications with substantial unmet need, including fibrosis, inflammatory pain, angiogenesis, cancer growth, and neurodegeneration. Genkyotex is currently developing two clinical stage, first-in-class NOX inhibitors and is conducting research on several other pre-clinical molecules.
For more information, visit us at www.genticel.com
This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only and are not otherwise available for distribution or sale.
|EU INVESTORS||US INVESTORS||MEDIA|
+33 1 44 71 94 92
+1 212 915 2578
+33 6 64 18 99 59 / +33 6 47 38 90 04